Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07370077

Research on Early Screening and Diagnosis of Pulmonary Nodules Based on Novel Non-invasive Technologies.

Sponsor: Chen KeZhong

View on ClinicalTrials.gov

Summary

This is a prospective observational study designed to address the clinical challenge posed by the high false-positive rate associated with CT imaging in early lung cancer screening. The primary objective is to develop a multi-omics technology for early lung cancer screening, leveraging \*\*exhaled breath metabolomics, plasma metabolomics, radiomics, and liquid biopsy. Based on large-sample detection data, the study aims to construct a \*\*multi-dimensional, sequential decision-making system\*\*. This system utilises the high accessibility of metabolomics for primary screening, combined with radiomics and ctDNA technologies for subsequent \*\*differentiation and definitive diagnosis. The research plans to prospectively enrol 300 patients with non-small cell lung cancer, along with corresponding subjects with benign nodules and healthy controls. By optimising the model using machine learning and deep learning algorithms (such as SVM, HRNet, and PAResNet), the ultimate goal is to establish a novel lung cancer early screening system characterised by \*\*high sensitivity, high accuracy, and high accessibility\*\*, enabling the precise differentiation and screening of healthy individuals, benign pulmonary nodules, and early-stage lung cancer.

Official title: Research on Precise Early Screening and Diagnosis of Pulmonary Nodules Based on a Novel Multidimensional Non-invasive Approach

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

1800

Start Date

2022-12-31

Completion Date

2026-06-30

Last Updated

2026-01-27

Healthy Volunteers

Yes

Conditions

Interventions

DIAGNOSTIC_TEST

Employing multi-omics diagnostic approaches to enhance diagnostic efficacy

The study will first systematically evaluate the efficacy and accessibility of metabolomics and radiomics in the early screening and diagnosis of lung cancer through retrospective data analysis of prospective databases and prospective cohort validation. Based on large-scale detection data, a novel multidimensional early-stage lung cancer screening system will be established. This system will employ metabolomics as the initial screening method, supplemented by multi-omics approaches including radiomics, cfDNA methylation fragment detection, TCR detection, and metabolomics for differential diagnosis and confirmation.

Locations (1)

Peking University People's Hospital

Beijing, Beijing Municipality, China